Population pharmacokinetic studies involved patients from various ethnicities, primarily Asian and Caucasian groups, because of the high prevalence of EGFR mutations in East Asian individuals with NSCLC, enabling significantly superior survival outcomes [46]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.